Current Cancer Therapy Reviewspublishes full-length review/mini reviews, original research articles, drug clinical trial studies and guest edited thematic issues on all the latest advances in clinical oncology, cancer therapy and pharmacology. The journal’s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in cancer therapy.
We invite you to submit your one page abstract along with your latest CV and list of publications to us for review, if you wish to publish your article in the journal. Send your abstract at firstname.lastname@example.org
Vadim S. Pokrovsky*, Vladimir A. Zolottsev, Alexandra S. Latysheva, Vasiliy A. Kudinov, Natalia Yu Anisimova, R.L.M. Almanza, Olga Yu Alekseeva, Konstantin K. Baskaev, Galina B. Smirnova, Yulia A. Borisova and Olga M. Ipatova
Cardiovascular & Hematological Agents in Medicinal Chemistryjournal invites Thematic Issue Proposals from scientists, researchers, medical doctors, experienced academicians and practitioners from universities and organizations around the world. You can send us your latest CV and Thematic Issue Proposal at email@example.com.
Cardiovascular & Hematological Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of new Cardiovascular & Hematological Agents. Each issue contains a series of timely in-depth/mini reviews, original research articles and drug clinical trial studies written by leaders in the field covering a range of current topics in Cardiovascular & Hematological medicinal chemistry.
The journal is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in cardiovascular & hematological drug discovery.
Bentham Science is pleased to announce an Institutional Member partnership with the Turkish university, Çukurova University Tropical Diseases Research and Application Center (TDRAC). The partnership provides the opportunity to the researchers, from the university, to publish their research under an Open Access license with specified fee concessions. This agreement is a continuation of Bentham Science Publishers’ vision to make transformative agreements with renowned institutions around the world and facilitate their researchers for publishing their work.
Tropical Disease Research and Application Center (TDRAC) was founded by Çukurova University and officially approved by “Turkiye Institution of Higher Education” in 1984. TDRAC has been involved in research studies on the diagnosis, molecular epidemiology, and detecting vectors of regional tropical and subtropical diseases like Leishmania, Tuberculosis, Malaria, and Amoebiasis. The center also conducts trainings for laboratory diagnosis and new and educational treatments since its foundation.
Bentham Science is a science, technology, and medical (STM) publisher, providing academic researchers and industrial professionals with the latest information in diverse fields of science and technology. Bentham Science currently publishes more than 100 journals in both electronic and printed formats. Our journals cover various disciplines in pharmaceutical research and development, medical subspecialties, engineering, technology, and social sciences. The journals are indexed in recognized indexing services, such as Journal Citation Reports/Science Edition, MEDLINE/Index Medicus, PubMed, Scopus, Chemical Abstracts, and EMBASE.
Current Chinese Science is a peer reviewed journal with over 70 sections headed by leading Chinese scientists as Co-Editors. The journal will cover important and emerging fields in agriculture, science, engineering, medicine and other areas. The journal aims to provide researchers and scholars a strong platform to publish their work and share their findings with readers around the world.
The separation of the brain from blood by the blood-brain barrier and the bloodcerebrospinal fluid (CSF) barrier poses unique challenges for the discovery and development of drugs targeting the central nervous system (CNS). This review will describe the role of transporters in CNS penetration and examine the relationship between unbound brain (Cu-brain) and unbound plasma (Cu-plasma) or CSF (CCSF) concentration. Published data demonstrate that the relationship between Cu-brain and Cu-plasma or CCSF can be affected by transporter status and passive permeability of a drug and CCSF may not be a reliable surrogate for CNS penetration. Indeed, CCSF usually over-estimates Cu-brain for efflux substrates and it provides no additional value over Cu-plasma as the surrogate of Cu-brain for highly permeable non-efflux substrates. A strategy described here for the evaluation of CNS penetration is to use in vitro permeability, P-glycoprotein (Pgp) and breast cancer resistance protein efflux assays and Cu-brain/Cu-plasma in preclinical species. Cu-plasma should be used as the surrogate of Cu-brain for highly permeable non-efflux substrates with no evidence of impaired distribution into the brain. When drug penetration into the brain is impaired, we recommend using (total brain concentration * unbound fraction in the brain) as Cu-brain in preclinical species or Cu-plasma/in vitro Pgp efflux ratio if Pgp is the major limiting mechanism for brain penetration. To read out more, please visit:https://www.eurekaselect.com/170606/article
Drug Metabolism Letterspublishes letters, original research articles, mini-reviews, thematic issues based on mini-reviews and letters, commentaries, technical notes and drug clinical trial studies on major advances in all areas of drug metabolism and disposition.
In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; bioactivation; recent developments for the identification of drug metabolites, reactive intermediate and glutathione conjugates.